Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Icatibant Acetate

FDA-approved product (injectable, subcutaneous), marketed as Firazyr, Icatibant Acetate.

Registered studies
33
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Icatibant Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angioedema
  • Hereditary angioedema

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Drugs used in hereditary angioedema
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

33registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Icatibant Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Icatibant Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Mitochondria and Chronic Kidney Disease

    NCT03177798 · start 2017-08-01

    Registered record
    Registry ID
    NCT03177798
    Conditions
    Hemodialysis-Induced Symptom; Mitochondrial Diseases
    Interventions
    Icatibant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-08-01
    Completion
    2018-12-31
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemodialysis-Induced Symptom; Mitochondrial Diseases
    InterventionIcatibant; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants

    NCT03888755 · start 2015-03-18

    Registered record
    Registry ID
    NCT03888755
    Conditions
    Hereditary Angioedema (HAE)
    Interventions
    Icatibant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-03-18
    Completion
    2016-02-12
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema (HAE)
    InterventionIcatibant
    PhasePhase 3
    Registry statusCompleted

  • Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

    NCT02045264 · start 2014-02-21

    Registered record
    Registry ID
    NCT02045264
    Conditions
    Hereditary Angioedema (HAE)
    Interventions
    Icatibant (30 mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-02-21
    Completion
    2014-02-27
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema (HAE)
    InterventionIcatibant (30 mg)
    PhasePhase 1
    Registry statusCompleted

  • Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema

    NCT01919801 · start 2013-12-02

    Registered record
    Registry ID
    NCT01919801
    Conditions
    Angiotensin Converting Enzyme Inhibitor Induced Angioedema
    Interventions
    Icatibant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-12-02
    Completion
    2015-08-22
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAngiotensin Converting Enzyme Inhibitor Induced Angioedema
    InterventionIcatibant; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

    NCT01386658 · start 2012-01-27

    Registered record
    Registry ID
    NCT01386658
    Conditions
    Hereditary Angioedema (HAE)
    Interventions
    icatibant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01-27
    Completion
    2018-03-12
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema (HAE)
    Interventionicatibant
    PhasePhase 3
    Registry statusCompleted

  • Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE

    NCT01457430 · start 2011-12

    Registered record
    Registry ID
    NCT01457430
    Conditions
    Hereditary Angioedema
    Interventions
    Icatibant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-12
    Completion
    2014-04
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema
    InterventionIcatibant
    PhasePhase 4
    Registry statusCompleted

  • Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema

    NCT01574248 · start 2011-08

    Registered record
    Registry ID
    NCT01574248
    Conditions
    ACE Inhibitor-associated Angioedema
    Interventions
    icatibant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2011-08
    Completion
    2016-02
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionACE Inhibitor-associated Angioedema
    Interventionicatibant; Placebo
    PhasePhase 4
    Registry statusTerminated

  • EASSI - Evaluation of the Safety of Self-Administration With Icatibant

    NCT00997204 · start 2009-09-25

    Registered record
    Registry ID
    NCT00997204
    Conditions
    Hereditary Angioedema
    Interventions
    Icatibant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-09-25
    Completion
    2011-06-22
    Enrolment
    151

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema
    InterventionIcatibant
    PhasePhase 3
    Registry statusCompleted

  • The Effect of Ischaemic-Reperfusion in Man - A Bradykinin Dependent Pathway

    NCT00965120 · start 2009-08

    Registered record
    Registry ID
    NCT00965120
    Conditions
    Ischaemic Heart Diseases
    Interventions
    Forearm vascular study; bradykinin receptor antagonist (HOE-140); Placebo (saline)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-08
    Completion
    2010-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschaemic Heart Diseases
    InterventionForearm vascular study; bradykinin receptor antagonist (HOE-140); Placebo (saline)
    PhaseNot applicable
    Registry statusCompleted

  • The Effect of Ischaemic-Reperfusion and Remote Ischaemic Preconditioning in Man - A Bradykinin Dependent Pathway

    NCT00965393 · start 2009-08

    Registered record
    Registry ID
    NCT00965393
    Conditions
    Ischaemic Heart Diseases
    Interventions
    Forearm vascular study; Placebo; bradykinin receptor antagonist (HOE-140)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-08
    Completion
    2010-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschaemic Heart Diseases
    InterventionForearm vascular study; Placebo; bradykinin receptor antagonist (HOE-140)
    PhaseNot applicable
    Registry statusCompleted

  • A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

    NCT00912093 · start 2009-07-16

    Registered record
    Registry ID
    NCT00912093
    Conditions
    Hereditary Angioedema
    Interventions
    Icatibant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-07-16
    Completion
    2010-10-01
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema
    InterventionIcatibant; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

    NCT01034969 · start 2009-07-10

    Registered record
    Registry ID
    NCT01034969
    Conditions
    Hereditary Angioedema (HAE)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-07-10
    Completion
    2024-05-31
    Enrolment
    1,761

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema (HAE)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema

    NCT00517582 · start 2007-09

    Registered record
    Registry ID
    NCT00517582
    Conditions
    Angioneurotic Edema
    Interventions
    HOE-140; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2007-09
    Completion
    2015-12
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAngioneurotic Edema
    InterventionHOE-140; Placebo
    PhasePhase 1
    Registry statusTerminated

  • Bradykinin Receptor Antagonism During Cardiopulmonary Bypass

    NCT00223704 · start 2006-05

    Registered record
    Registry ID
    NCT00223704
    Conditions
    Cardiopulmonary Bypass; Inflammation; Fibrinolysis; Surgery
    Interventions
    HOE 140; Aminocaproic Acid; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2006-05
    Completion
    2012-06
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiopulmonary Bypass; Inflammation; Fibrinolysis; Surgery
    InterventionHOE 140; Aminocaproic Acid; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis

    NCT00303056 · start 2006-02

    Registered record
    Registry ID
    NCT00303056
    Conditions
    Joint Disease
    Interventions
    HOE140 Icatibant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-02
    Completion
    2007-07
    Enrolment
    590

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionJoint Disease
    InterventionHOE140 Icatibant
    PhasePhase 2
    Registry statusCompleted